학술논문

Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 1 December 2016, 22(23):5688-5695)
Subject
Language
English
ISSN
15573265
10780432